title: [Study methods of drugs in Alzheimer disease].
abstract: The availability of new drugs for Alzheimer's disease, with different pharmacological profiles, leads to a redefinition the relevant methodology for developing drugs in this indication, including the inclusion/exclusion criteria, the duration of the studies, and therefore, the relevant guidelines. This was the purpose of the Giens Round-table devoted to the new methodology for drug development in Alzheimer disease.
authors.affiliation: Fédération de Neurologie, Hôpital Salpêtrière 47 Bd de l'hôpital, Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Dubois
authors.forename: B
authors.initials: B
authors.lastname: Stehlé
authors.forename: J P
authors.initials: JP
authors.lastname: Lehner
authors.forename: C
authors.initials: C
authors.lastname: Derouesné
authors.forename: M
authors.initials: M
authors.lastname: Bourin
authors.forename: Y
authors.initials: Y
authors.lastname: Lamour
authors.forename: O
authors.initials: O
authors.lastname: Blin
authors.forename: G
authors.initials: G
authors.lastname: Jourdain
authors.forename: A
authors.initials: A
authors.lastname: Alperovitch
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D000818:Animals; D002986:Clinical Trials as Topic; D003071:Cognition / Q000187:drug effects; D004341:Drug Evaluation; D005602:France; D017408:Guidelines as Topic; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use
chemical_list: D018696:Neuroprotective Agents
vernacular_title: Méthodes d'étude des médicaments dans la maladie de l'Alzheimer.